ImmunityBio Inc. (IBRX) exhibits 96.0% gross margins and -27.3% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 7.1% implied options volatility.
Sustained 96.0% gross profitability converts into -60.0% operating margin and -27.3% ROIC, outpacing sector cost of capital.
ROIC: -27.3% // GM: 96.0%YoY revenue trajectory of +180.0% paired with -3.33% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +180.0% // FCF YLD: -3.33%Altman Z-Score of 0.45 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.45 // F-SCORE: 6/9Trading at 24.0x trailing P/E (29.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.1% implied move with a 0.73 put/call ratio around $9.00 max pain.
IMPL MOVE: ±7.1% // P/C: 0.73Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -60.0% net margins.
NET MARGIN: -60.0% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for IBRX & activate live FRED threshold breach alerts.